Celera, Abott revise alliance
ALAMEDA, Calif. Celera Corp. and Abbott have revised the strategic alliance that they started in June 2002, the two companies announced Monday.
Under the revised distribution agreement, Abbott will distribute unspecified molecular products that Celera manufactures, while another agreement stipulates that Celera will receive royalties on the sale of its m2000 reagents, instruments, service and related products, and Abbott will receive royalties on some Celera genetic tests. The new distribution agreement will have a five-year term with two two-year renewal periods, and the new royalty agreement expires in 2017.
“We’ve been pleased with our relationship with Abbott as we?ve built a successful market position in molecular diagnostics over the past six years,” Celera chief executive officer Kathy Ordonez said in a statement. “Moreover, we believe the new arrangements will provide greater financial clarity for Celera’s investors.”
FDA tentatively approves Seroquel generic
JERUSALEM The Food and Drug Administration has given tentative approval to a generic version of AstraZeneca’s antipsychotic Seroquel.
Teva announced last Tuesday that the FDA had granted the tentative approval for generic Seroquel (quetiapine fumarate) in 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 300 mg and 400 mg strengths.
The branded version of the drug had sales of about $3.8 billion in the United States for the 12 months ending Sept. 30, according to IMS Health data.
Teva expects to receive final approval after resolving patent litigation with AstraZeneca.
Zerit generic gets FDA approval
PITTSBURGH The Food and Drug Administration has approved a generic version of Bristol-Myers Squibb’s Zerit by Mylan’s Indian subsidiary, Mylan announced Tuesday.
The FDA approved Matrix Labs? stavudine capsules USP in 15 mg, 20 mg, 30 mg and 40 mg strengths. The drug is an antiretroviral used to treat HIV infection in combination with other antiretroviral drugs. The branded version of the drug had sales of about $54 million in the 12 months ending Sept. 30, according to IMS Health data.
Mylan owns a 71.5% stake in Matrix.